Featured Jobs
|
BPAS
|
|
Automotive Industries Trust Funds
|
|
Nova 401(k) Associates
|
|
Compass
|
|
The Pension Source
|
|
Mergers & Acquisition Specialist Compass
|
|
Pentegra
|
|
Strongpoint Partners
|
|
Relationship Manager for Defined Benefit/Cash Balance Plans MM Daybright Financial
|
|
Relationship Manager for Defined Contributions KP Daybright Financial
|
|
Independent Retirement
|
|
BPAS
|
|
Retirement Plan Onboarding Specialist Compass
|
|
Attorney - ERISA, Benefits, & PRT Securian Financial Group
|
|
Combo Retirement Plan Administrator Strongpoint Partners
|
|
Senior Client Service Specialist EPIC RPS
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
|
GLP-1 Indications Continue to Expand: Potential Approvals Expected Through 2026
Lockton 
Aug. 26, 2025 "Wegovy has now received FDA approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis.... The growing GLP-1 approval pipeline has significant implications for employers in terms of cost, coverage, and employee access. Throughout the end of 2026, new indications across a broad range of clinical applications are expected that employers should be aware of[.]" MORE >> |
| Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
| An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |